Your browser doesn't support javascript.
loading
Targeting hepatocarcinogenesis model in C56BL6 mice with pan-aurora kinase inhibitor Danusertib.
Gavriilidis, Paschalis; Poutahidis, Theofilos; Giakoustidis, Alexander; Makedou, Kali; Angelopoulou, Katerina; Hardas, Alexander; Andreani, Paola; Zacharioudaki, Argyro; Saridis, George; Gargavanis, Athanasios; Louri, Eleni; Antoniadis, Nikolaos; Karampela, Eleftheria; Psychalakis, Nikolaos; Michalopoulos, Antonios; Papalois, Apostolos; Iliadis, Stavros; Mudan, Satvinder; Azoulay, Daniel; Giakoustidis, Dimitrios.
Afiliação
  • Gavriilidis P; Department of Hepato-Pancreato-Biliary and Liver Transplant surgery, Queen Elizabeth University Hospitals Birmingham NHS Foundation Trust, B15 1NU, UK.
  • Poutahidis T; Division of Transplant Surgery, Department of Surgery, School of Medicine, Faculty of Health Sciences, Aristotle University and Hippokration General Hospital, Thessaloniki, Greece.
  • Giakoustidis A; Laboratory of Pathology, School of Veterinary Medicine, Faculty of Health Sciences, Aristotle University of Thessaloniki.
  • Makedou K; Academic Department of Surgery, The Royal Marsden Hospital, London, UK.
  • Angelopoulou K; Laboratory of Biochemistry, School of Medicine, Faculty of Health Sciences, Aristotle University of Thessaloniki.
  • Hardas A; Laboratory of Biochemistry and Toxicology, School of Veterinary Medicine, Faculty of Health Sciences, Aristotle University of Thessaloniki.
  • Andreani P; Laboratory of Pathology, School of Veterinary Medicine, Faculty of Health Sciences, Aristotle University of Thessaloniki.
  • Zacharioudaki A; Service de Chirurgie Digestive et Hépatobiliaire, Hôpital Henri Mondor, Assistance Publique-Hôpitaux de Paris-Université Paris-Est, Créteil, France.
  • Saridis G; Experimental and Research Center ELPEN Pharmaceuticals, Athens, Greece.
  • Gargavanis A; Laboratory of Pathology, School of Veterinary Medicine, Faculty of Health Sciences, Aristotle University of Thessaloniki.
  • Louri E; Division of Transplant Surgery, Department of Surgery, School of Medicine, Faculty of Health Sciences, Aristotle University and Hippokration General Hospital, Thessaloniki, Greece.
  • Antoniadis N; Academic Department of Surgery, The Royal Marsden Hospital, London, UK.
  • Karampela E; Division of Transplant Surgery, Department of Surgery, School of Medicine, Faculty of Health Sciences, Aristotle University and Hippokration General Hospital, Thessaloniki, Greece.
  • Psychalakis N; Experimental and Research Center ELPEN Pharmaceuticals, Athens, Greece.
  • Michalopoulos A; Experimental and Research Center ELPEN Pharmaceuticals, Athens, Greece.
  • Papalois A; Propaedeutic Division of Surgery, Department of Surgery School of Medicine, Faculty of Health Sciences, Aristotle University and AHEPA University Hospital, Thessaloniki, Greece.
  • Iliadis S; Experimental and Research Center ELPEN Pharmaceuticals, Athens, Greece.
  • Mudan S; Laboratory of Biochemistry, School of Medicine, Faculty of Health Sciences, Aristotle University of Thessaloniki.
  • Azoulay D; Academic Department of Surgery, The Royal Marsden Hospital, London, UK.
  • Giakoustidis D; Service de Chirurgie Digestive et Hépatobiliaire, Hôpital Henri Mondor, Assistance Publique-Hôpitaux de Paris-Université Paris-Est, Créteil, France.
J Cancer ; 9(5): 914-922, 2018.
Article em En | MEDLINE | ID: mdl-29581770
ABSTRACT

Background:

To elucidate the expression of Aurora kinases (AURK) and the anticancer effects of pan-aurora kinase inhibitor Danusertib in hepatocarcinogenesis model in C56Bl6 mice.

Methods:

Thirty mice C56Bl6 were randomly divided into Group A or control, Group B animals who underwent experimental hepatocarcinogenesis with diethylnitrosamine (DEN), and Group C animals with DEN-induced hepatocarcinogenenesis that treated with pan-aurora kinase inhibitor Danusertib. Primary antibodies for immunochistochemistry (IHC) included rabbit antibodies against Ki-67, DKK1, INCENP, cleaved caspase-3, NF-κB p65, c-Jun, ß-catenin. Hepatocyte growth factor receptor (C-MET/HGFR) and Bcl-2 antagonist of cell death (BAD) serum levels were determined using a quantitative sandwich enzyme immunoassay technique.

Results:

Inhibition of AURK reduced the number of DEN-induced liver tumours. Apoptosis and proliferation was very low in both DEN-induced and anti- AURK groups respectively. The hepatocellular adenoma cells of DEN-treated mice uniformly had ample nuclear INCENP whereas in anti- AURK markedly decreased. Expression of ß-catenin, NF-kB and c-Jun did not differ in liver tumors of both AURK -depleted and non-depleted mice.

Conclusions:

Depletion of AURK reduced the number of DEN-induced hepatic tumours. However, their size did not differ significantly between the groups.
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2018 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2018 Tipo de documento: Article